LYNPARZA®

Drug Information Related Patent

Hold Company

ASTRAZENECA

Learn More

Dosage and Administration

TABLET;ORAL

Specification

100MG; 150MG

Indication

LYNPARZA® is used to treat specific types of ovarian cancer, breast cancer, fallopian tube cancer, pancreatic cancer, prostate cancer, and peritoneal cancer.

Use

Instructions for Use

API

OLAPARIB

API Structure

We Supply

OLAPARIB

Note:

USP/In-house Standard
Facility GMP
DMF/USMF/ASMF

null

Note:

null

Note:

null

Drug Patent

Patent No	Expiration Date
11633396	2029/10/7
7449464	2024/10/11
7981889	2024/10/11
8071579	2027/8/12
8143241	2027/8/12
8475842	2029/12/31
8859562	2031/8/4
8912187	2024/3/12
9169235	2024/3/12
9566276	2024/3/12

API Patent

Patent No	Expiration Date
7449464	2024/10/11
7981889	2024/10/11
8071579	2027/8/12

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION

Tel:
E-mail:
Address:
WhatsAPP

Member of

CERTIFICATION